Page No.: 3

Amendment to the Claims:

Cancel Claims 17, 18, 19, 21, 22, and 23.

Listing of Claims:

1. (original) A compound of structural formula I:

$$R^{6}$$
 R^{5}
 R^{4}
 R^{3}

I

wherein:

each n is independently 0, 1, 2, or 3;

X is selected from S, S(O), S(O)₂, CH₂, CHF, and CF₂;

R¹ is hydrogen or -CN;

 R^2 is selected from the group consisting of

hydrogen,

C₁₋₆ alkyl, wherein alkyl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, CO₂H,

C₁₋₆ alkyloxycarbonyl, and

(CH₂)_n-aryl, wherein aryl is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, CO₂H,

C₁₋₆ alkyloxycarbonyl, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₆ alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;

R³, R⁴, R⁵, and R⁶ are each independently selected from the group consisting of

```
hydrogen,
cyano,
hydroxy,
C1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to five halogens,
C1-6 alkoxy, wherein alkoxy is unsubstituted or substituted with one to five halogens,
(CH2)n-COOH,
(CH2)n-COOC1-6 alkyl,
(CH2)n-CONR<sup>7</sup>R<sup>8</sup>,
(CH2)n-NR<sup>10</sup>SO2R<sup>9</sup>,
(CH2)n-NR<sup>10</sup>CONR<sup>7</sup>R<sup>8</sup>,
(CH2)n-NR<sup>10</sup>CONR<sup>7</sup>R<sup>8</sup>,
(CH2)n-NR<sup>10</sup>COR<sup>10</sup>,
(CH2)n-NR<sup>10</sup>COR<sup>10</sup>,
(CH2)n-NR<sup>10</sup>COR<sup>10</sup>,
(CH2)n-NR<sup>10</sup>CO2R<sup>9</sup>,
(CH2)n-aryl, wherein aryl is unsubstituted or substituted with one to five substituents
```

independently selected from halogen, hydroxy, CO₂H, C₁₋₆ alkyloxycarbonyl, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, and C₁₋₆ alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens,

wherein any methylene (CH₂) carbon atom in R³, R⁴, R⁵, and R⁶ is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C₁₋₄ alkyl unsubstituted or substituted with one to five halogens;

R⁷ and R⁸ are each independently selected from the group consisting of

hydrogen,
(CH₂)_n-phenyl,
(CH₂)_n-C₃₋₆ cycloalkyl, and
C₁₋₁₀ alkyl,

wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C₁₋₆ alkyl, and C₁₋₆ alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens; or

R⁷ and R⁸ together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said heterocyclic ring is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy,

C₁₋₆ alkyl, and C₁₋₆ alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;

 R^9 is selected from the group consisting of $(CH_2)_n$ -phenyl, $(CH_2)_n$ -C3-6 cycloalkyl, and C_{1-6} alkyl, wherein alkyl is unsubstituted or substituted with one to five halogens and wherein phenyl and cycloalkyl are unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C_{1-6} alkyl, and C_{1-6} alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens, and wherein any methylene (CH_2) carbon atom in R^9 is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C_{1-4} alkyl unsubstituted or substituted with one to five halogens; and

each R¹⁰ is hydrogen or R⁹.

2. (original) The compound of Claim 1 of structural formula Ia wherein the carbon atom marked with an * has the stereochemical configuration as depicted in formula Ia:

$$R^{6}$$
 R^{5}
 R^{4}
 R^{3}
 R^{3}

- 3. (original) The compound of Claim 1 wherein X is S, S(O), or S(O)2.
- 4. (original) The compound of Claim 3 wherein R¹ is hydrogen.
- 5. (original) The compound of Claim 2 wherein X is S, S(O), or $S(O)_2$.

Page No.: 6

6. (original) The compound of Claim 1 wherein X is CH₂, CHF, or CF₂.

7. (original) The compound of Claim 6 wherein R¹ is hydrogen.

8. (original) The compound of Claim 2 wherein X is CH₂, CHF, or CF₂.

9. (original) The compound of Claim 1 wherein R² is hydrogen, methyl, or phenyl.

10. (original) The compound of Claim 9 wherein R³, R⁴, R⁵ and R⁶ are each independently selected from the group consisting of hydrogen, halogen, trifluoromethyl, trifluoromethoxy, carboxy, and COOC₁₋₄ alkyl.

11. (original) The compound of Claim 10 wherein R⁴ and R⁶ are hydrogen.

12. (original) The compound of Claim 11 of structural formula II selected from the group consisting of:

$$R^5$$
 R^3
 R^3
 R^3
 R^3
 R^3
 R^3

<u>X</u>	<u>R</u> 2	<u>R</u> 3	<u>R</u> 5
S	H	Н	Cl
CH ₂	Н	Н	Cl
CH ₂	Н	Н	OCF3
CH ₂	Н	Н	CF3
CH ₂	Н	CO ₂ H	Н
CH ₂	Н	CO ₂ Et	Н
СН2	Н	Н	СО2Н

Case No.: Page No.:

7

CH ₂	Н	Н	CO ₂ Et
CH ₂	Н	CF3	Н
CF ₂	Н	CONH <i>n</i> -Dec	Н
CH ₂	Me	Н	Н
CH ₂	Ph	Н	Н

- 13. (original) A pharmaceutical composition which comprises a compound of Claim 1 and a pharmaceutically acceptable carrier.
- 14. (original) A method for treating diabetes in a mammal in need thereof which comprises the administration to the mammal of a therapeutically effective amount of a compound of Claim 1.
- 15. (original) A method for treating non-insulin dependent (Type 2) diabetes in a mammal in need thereof which comprises the administration to the mammal of a therapeutically effective amount of a compound of Claim 1.
- 16. (original) A method for treating hyperglycemia in a mammal in need thereof which comprises the administration to the mammal of a therapeutically effective amount of a compound of Claim 1.

17-19. (cancelled)

- 20. (original) The pharmaceutical composition of Claim 13 further comprising one or more additional active ingredients selected from the group consisting of:
 - (a) a second dipeptidyl peptidase IV inhibitor;
- (b) an insulin sensitizer selected from the group consisting of a PPAR γ agonist, a PPAR α / γ dual agonist, a PPAR α agonist, a biguanide, and a protein tyrosine phosphatase-1B inhibitor;
 - (c) an insulin or insulin mimetic;
 - (d) a sulfonylurea or other insulin secretagogue;
 - (e) an α -glucosidase inhibitor;
 - (f) a glucagon receptor antagonist;
 - (g) GLP-1, a GLP-1 mimetic, or a GLP-1 receptor agonist;
 - (h) GIP, a GIP mimetic, or a GIP receptor agonist;

Page No.:

- (i) PACAP, a PACAP mimetic, or a PACAP receptor agonist;
- (j) a cholesterol lowering agent such as (i) HMG-CoA reductase inhibitor, (ii) sequestrant, (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPAR α agonist, (v) PPAR α / γ dual agonist, (vi) inhibitor of cholesterol absorption, (vii) acyl CoA:cholesterol acyltransferase inhibitor, and (viii) anti-oxidant;
 - (k) a PPAR δ agonist;
 - (l) an antiobesity compound;
 - (m) an ileal bile acid transporter inhibitor;
 - (n) an anti-inflammatory agent; and
 - (o) an antihypertensive agent.

21-23 (cancelled)